Phospho-specific antibodies’ typical purpose is to enable researchers to detect changes in proteins. They will exclusively bind to the amino acid sequence on a protein that has been phosphorylated (which is both a physical & chemical change) and do not bind to the same amino acid sequence on said protein if it lacks said phosphorylation. This aids in being able to clearly see and understand the data produced from this particular protein modification.
IF (Immunofluorescence) (Immunofluorescence staining of methanol-fixed Hela cells using SEK1/MKK4(Phospho-Ser80) Antibody.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using SEK1/MKK4(Phospho-Ser80) Antibody(left) or the same antibody preincubated with blocking peptide(right).)
WB (Western Blot) (Western blot analysis of extracts from HepG2 cells untreated or treated with EGF using SEK1/MKK4(Phospho-Ser80) Antibody.)
Immunofluorescence, Immunohistochemistry, Western Blot
Purity
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human lung carcinoma tissue using PKCth(Phospho-Ser695) Antibody(left) or the same antibody preincubated with blocking peptide(right).)
WB (Western Blot) (Western blot analysis of extracts from 293 cells untreated or treated with PMA using PKCth(Phospho-Ser695) Antibody.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IF (Immunofluorescence) (Immunofluorescence staining of methanol-fixed Hela cells using SEK1/MKK4(Phospho-Thr261) Antibody.)
IHC (Immunohistochemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using SEK1/MKK4(Phospho-Thr261) Antibody(left) or the same antibody preincubated with blocking peptide(right).)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using MEK1/MEK2(Phospho-Ser217/Ser221) Antibody(left) or the same antibody preincubated with blocking peptide(right).)
WB (Western Blot) (Western blot analysis of extracts from Hela cell untreated or treated with UV MEK1/MEK2(Phospho-Ser217/Ser221) Antibody)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using IkB-e(Phospho-Ser22) Antibody(left) or the same antibody preincubated with blocking peptide(right).)
WB (Western Blot) (Western blot analysis of extracts from 293 cells untreated or treated with TNF using IkB-e(Phospho-Ser22) Antibody.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
WB (Western Blot) (Western blot analysis of extracts from K562 cells, treated with calf intestinal phosphatase (CIP), using Myc (Phospho-Ser62) Antibody.)
IF (Immunofluorescence) (Immunofluorescence staining of methanol-fixed Hela cells using Myc(Phospho-Ser62) Antibody.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human pancreas tissue using Raf1 (Phospho-Tyr341) antibody (left)or the same antibody preincubated with blocking peptide (right).)
WB (Western Blot) (Western blot analysis of extracts from Jurkat cells treated with Paclitaxel using Raf1 (Phospho-Tyr341) Antibody.The lane on the right is treated with the antigen-specific peptide.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IHC (Immunohistochemistry) (Immunohistochemical analysis of paraffin- embedded human lung carcinoma tissue using NFκB-p65 (Phospho-Ser276) antibody.)
IHC (Immunohistochemistry) (Immunohistochemical analysis of paraffin- embedded human breast carcinoma tissue using NFκB-p65 (Phospho-Ser276) antibody.)
IHC (Immunohistochemisry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using NFκB-p65 (Phospho-Ser276) Antibody (left) or the same antibody preincubated with blocking peptide (right).)
WB (Western Blot) (Western blot analysis of extract from Hela cells using NF-κB p65 (phospho-Ser276) antibody. Lane 1: The antibody is not preincubated with blocking peptides. Lane 2: The antibody is preincubated with non- phospho peptide blocking peptides. Lane 3: The antibody is preincubated with phospho peptide blocking peptides.)
IF (Immunofluorescence) (Immunofluorescence staining of methanol-fixed Hela cells using NFκB-p65 (Phospho-Ser276) Antibody.)
Immunofluorescence, Immunohistochemistry, Western Blot
Purity
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
WB (Western Blot) (Western blot analysis of extracts from COLO205 cells using cofilin (Ab-1022) antibody (Line 1 and 2) and cofilin (phospho-Ser3) antibody (Line 3 and 4).)
IHC (Immunohistochemistry) (P-Peptide-+ Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using cofilin (phospho-Ser3) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
WB (Western Blot) (Western blot analysis of extracts from K562 cells, using Connexin43 (Phospho-Ser367) antibody.)
IHC (Immunohistochemistry) (P-peptide-+ Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue, using Connexin43 (Phospho-Ser367) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatogramphy using non-phosphopeptide corresponding to the phosphorylation site.
IHC (Immunohiostchemistry) (Immunohistochemistry analysis of paraffin-embedded human brain tissue using Synapsin1 (Phospho-Ser62) antibody. Western blot analysis of extracts from HeLa cells, treated with Anisomycin (25ug/ml, 30mins), using Synapsin1 (Phospho-Ser62) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
WB (Western Blot) (P-peptide-+ Western blot analysis of extracts from LOVO cells, using Calcium Sensing Receptor (Phospho-Thr888) antibody. Immunofluorescence analysis of HeLa cells, using Calcium Sensing Receptor (Phospho-Thr888) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
IHC (Immunohiostchemistry) (Immunohistochemistry analysis of paraffin-embedded human lymph node tissue using Neutrophil Cytosol Factor 1 (Phospho-Ser328) antibody. Neutrophil Cytosol Factor 1 (Phospho-Ser328) antibody reacts with epitope-specific phosphopeptide and corresponding non-phosphopeptide. The absorbance readings at 450 nM are shown in the ELISA figure.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
Pricing
IHC (Immunohistochemistry) (Immunohistochemistry analysis of paraffin-embedded human lung carcinoma tissue, using Centaurin-beta1 (Phospho-Ser554) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
IF (Immunofluorescence) (Immunofluorescence analysis of Rat heart tissue with Phospho-AMPK?1/2 (Thr183/172) Polyclonal Antibody at dilution of 1:200)
IHC (Immunohiostchemistry) (Immunohistochemistry of paraffin-embedded mouse brain with Phospho-AMPK?1/2 (Thr183/172) Polyclonal Antibody at dilution of 1:50)
WB (Western Blot) (Western Blot analysis of various cells with Phospho-AMPK?1/2 (Thr183/172) Polyclonal Antibody at dilution of 1:500)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of IKK beta (pY199) staining in human breast cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.)
WB (Western Blot) (Western blot analysis of IKK beta (pY199) expression in HeLa LPS-treated (A), Raw264.7 LPS-treated (B), PC12 LPS-treated (C) whole cell lysates.)
ELISA (Direct ELISA antibody dose-response curve using Anti-GSK3 beta (pS9) Antibody. Antigen (phosphopeptide and non-phosphopeptide) concentration is 5 ug/ml. Goat Anti-Rabbit IgG (H&L) - HRP was used as the secondary antibody, and signal was developed by TMB substrate.)
IF (Immunofluorescence) (Immunofluorescent analysis of GSK3 beta (pS9) staining in MCF7 cells. Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with the primary antibody in 3% BSA-PBS and incubated overnight at 4 °C in a hidified chamber. Cells were washed with PBST and incubated with a AF488-conjugated secondary antibody (green) in PBS at room temperature in the dark. Phalloidin - AF594 was used to stain the cytoplasm (red). DAPI was used to stain the cell nuclei (blue).)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of GSK3 beta (pS9) staining in human breast cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.)
WB (Western Blot) (Western blot analysis of GSK3 beta (pS9) expression in MCF7 (A), NIH3T3 (B), PC12 (C) whole cell lysates.)
IF (Immunofluorescence) (Immunofluorescent analysis of Cofilin (pS3) staining in HeLa cells. Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with the primary antibody in 3% BSA-PBS and incubated overnight at 4 °C in a humidified chamber. Cells were washed with PBST and incubated with a DyLight 594-conjugated secondary antibody (red) in PBS at room temperature in the dark.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of Cofilin (pS3) staining in human breast cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.)
WB (Western Blot) (Western blot analysis of Cofilin (pS3) expression in Jurkat (A), HeLa (B), MCF7 (C), A431 (D) whole cell lysates.)
IF (Immunofluorescence) (Immunofluorescent analysis of IKB alpha (pS32/S36) staining in Raw264.7 cells. Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with the primary antibody in 3% BSA-PBS and incubated overnight at 4 °C in a humidified chamber. Cells were washed with PBST and incubated with a DyLight 594-conjugated secondary antibody (red) in PBS at room temperature in the dark.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of IKB alpha (pS32/S36) staining in human breast cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.)
WB (Western Blot) (Western blot analysis of IKB alpha (pS32/S36) expression in HepG2 TNFa-treated (A), Raw264.7 TNFa-treated (B), PC12 TNFa-treated (C) whole cell lysates.)
IF (Immunofluorescence) (Immunofluorescent analysis of NF-kappaB p65 (pS311) staining in PC12 cells. Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with the primary antibody in 3% BSA-PBS and incubated overnight at 4 °C in a humidified chamber. Cells were washed with PBST and incubated with a DyLight 594-conjugated secondary antibody (red) in PBS at room temperature in the dark.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of NF-kappaB p65 (pS311) staining in human breast cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.)
WB (Western Blot) (Western blot analysis of NF-kappaB p65 (pS311) expression in HeLa TNFa-treated (A), mouse kidney (B), PC12 UV-treated (C) whole cell lysates.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of NF-kappaB p65 (pS276) staining in human breast cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.)
WB (Western Blot) (Western blot analysis of NF-kappaB p65 (pS276) expression in HeLa TNFa-treated (A), mouse kidney (B), PC12 UV-treated (C) whole cell lysates.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of FGFR1 (pY766) staining in human breast cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.)
WB (Western Blot) (Western blot analysis of FGFR1 (pY766) expression in HepG2 EGF-treated (A), SP2/0 EGF-treated (B), PC12 EGF-treated (C) whole cell lysates.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of NF-kappaB p105/p50 (pS337) staining in human breast cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.)
WB (Western Blot) (Western blot analysis of NF-kappaB p105/p50 (pS337) expression in HeLa (A), HEK293T TNF-treated (B), NIH3T3 (C), Raw264.7 (D), rat liver (E) whole cell lysates.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of c-Jun (pT91) staining in human breast cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.)
WB (Western Blot) (Western blot analysis of c-Jun (pT91) expression in NIH3T3 Anisomycin-treated (A) whole cell lysates.)
IHC (Immunohiostchemistry) (Immunohistochemistry analysis of paraffin-embedded human brain tissue using PDK1 (Phospho-Tyr9) antibody. PDK1 (Phospho-Tyr9) antibody reacts with epitope-specific phosphopeptide and corresponding non-phosphopeptide. The absorbance readings at 450 nM are shown in the ELISA figure.)
Affinity-purified fromrabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
IHC (Immunohiostchemistry) (Immunohistochemistry analysis of paraffin-embedded human breast carcinoma tissue using Retinoic Acid Receptor alpha (Phospho-Ser77) antibody. Western blot analysis of extracts from Jurkat cells treated with PMA (125ng/ml, 30mins), using Retinoic Acid Receptor alpha (Phospho-Ser77) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody againstnon-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
IHC (Immunohiostchemistry) (Immunohistochemistry analysis of paraffin-embedded human breast carcinoma tissue using S6 Ribosomal Protein (Phospho-Ser235+Ser236) antibody. Western blot analysis of extracts from 293 cells treated with TNF, using S6 Ribosomal Protein (Phospho-Ser235+Ser236) antibody.)
S6 Ribosomal Protein (Phospho-Ser235+Ser236) Antibody
Gene Names
RPS6; S6
Reactivity
Human, Mouse, Rat
Applications
Immunohistochemistry, Western Blot
Purity
Affinity-purified fromrabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
Pricing
WB (Western Blot) (Western blot analysis of extracts from 293 cells and K562 cells treated with EGF, using EGFR (Phospho-Ser695) antibody.)
Affinity-purified fromrabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
WB (Western Blot) (Western blot analysis of extract from MDA-MB-435 cells untreated or treated with UV, using MKK6 (Ab-207) antibody and MKK6 (phospho-Ser207) antibody.)
IHC (Immunohistochemistry) (P-Peptide-+ Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue, using MKK6 (phospho-Ser207) antibody.)
Immunofluorescence, Immunohistochemistry, Western Blot
Purity
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatogramphy using non-phosphopeptide corresponding to the phosphorylation site.
WB (Western Blot) (Western blot analysis of extracts from A431 cells (Lane 1 and 2) and EC-304 cells (Lane 3) using Keratin 18 (Phospho-Ser33) antibody.)
IHC (Immunohistochemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using Keratin 18 (Phospho-Ser33) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
WB (Western Blot) (Western blot analysis of the extracts from HeLa cells using Paxillin (Ab-118) antibody and Paxillin (phospho-Tyr118) antibody.)
IHC (Immunohistochemistry) (P-Peptide-+ Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using Paxillin (phospho-Tyr118) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
WB (Western Blot) (Western blot analysis of extract from MDA-MB-435 cells untreated or treated with UV, using MKK3 (Ab-189) antibody and MKK3 (phospho-Ser189) antibody.)
IHC (Immunohistochemistry) (P-Peptide-+ Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue, using MKK3 (phospho-Ser189) antibody.)
Immunofluorescence, Immunohistochemistry, Western Blot
Purity
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatogramphy using non-phosphopeptide corresponding to the phosphorylation site.
WB (Western Blot) (Western blot analysis of extracts from COLO205 cells using cofilin (Ab-1022) antibody and cofilin (phospho-Ser3) antibody.)
IHC (Immunohistochemistry) (P-Peptide-+ Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using cofilin (phospho-Ser3) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
IF (Immunofluorescence) (Immunofluorescent analysis of ACLY staining in HeLa cells. Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with the primary antibody in 3% BSA-PBS and incubated overnight at 4 °C in a humidified chamber. Cells were washed with PBST and incubated with a DyLight 594-conjugated secondary antibody (red) in PBS at room temperature in the dark. DAPI was used to stain the cell nuclei (blue).)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of ACLY staining in human liver formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.)
WB (Western Blot) (Western blot analysis of ACLY expression in Jurkat (A), Hela (B) whole cell lysates.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of VASP (pS157) staining in human breast cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.)
WB (Western Blot) (Western blot analysis of VASP (pS157) expression in C6 PMA-treated (A), HuvEc (B) whole cell lysates.)
Human (Identities = 100%, Positives = 100%) Rat (Identities = 90%, Positives = 100%)
Applications
Immunohistochemistry, Western Blot
Purity
Affinity-purified fromrabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
IHC (Immunohiostchemistry) (Immunohistochemistry analysis of paraffin-embedded human lung carcinoma tissue using Caspase 9 (Phospho-Thr125) antibody. Western blot analysis of extracts from HeLa cells, treated with TNF (20ng/ml, 5mins) and calyculinA (50ng/ml, 15mins), using Caspase 9 (Phospho-Thr125) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
IF (Immunofluorescence) (P-peptide-+ Immunofluorescence analysis of LOVO cells, using IkappaB-alpha (Phospho-Ser32/Ser36) antibody.)
IHC (Immunohiostchemistry) (Immunohistochemistry analysis of paraffin-embedded human breast carcinoma tissue using IkappaB-alpha (Phospho-Ser32/Ser36) antibody. Western blot analysis of extracts from COS-7 cells, using IkappaB-alpha (Phospho-Ser32/Ser36) antibody.)
Immunofluorescence, Immunohistochemistry, Western Blot
Purity
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
WB (Western Blot) (Western blot analysis of extracts from Jurkat cells untreated or treated with PMA (1ng/ml, 15mins), using Stathmin 1 (Ab-24) antibody (Line 1 and 2) and Stathmin 1 (phospho-Ser24) antibody (Line 3 and 4).)
IHC (Immunohistochemistry) (P-Peptide-+ Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using Stathmin 1 (phospho-Ser24) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
WB (Western Blot) (Western blot analysis of extracts from 293 cells, untreated or treated with serum(15%), using p70 S6 Kinase (Ab-424) antibody (Line 1 and 2) and p70 S6 Kinase (Phospho-Ser424) antibody (Line 3 and 4).)
IHC (Immunohistochemistry) (P-peptide-+ Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using p70 S6 Kinase (Phospho-Ser424) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatogramphy using non-phosphopeptide corresponding to the phosphorylation site.
IF (Immunofluorescence) (P-peptide-+ Immunofluorescence analysis of HeLa cells, using S6 Ribosomal Protein (Phospho-Ser240) antibody.)
IHC (Immunohiostchemistry) (Immunohistochemistry analysis of paraffin-embedded human skeletal muscle tissue using S6 Ribosomal Protein (Phospho-Ser240) antibody. Western blot analysis of extracts from HeLa cells, treated with TNF-a (20ng/ml, 2mins), using S6 Ribosomal Protein (Phospho-Ser240) antibody.)
Immunofluorescence, Immunohistochemistry, Western Blot
Purity
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
WB (Western Blot) (Detection of Phospho 53BP1 (S25) by western blot. Samples: Whole cell lysate (30 ug or 15 ug for WB; 1 mg for IP, 20% of IP loaded) from HEK293T cells that were mock treated or treated with NCS (200 ng/ml; 1h). Antibodies: Affinity purified rabbit anti-Phospho 53BP1 antibody AAA211074 (lot no. AAA211074-2) at 0.04 ug/ml (A) and 0.1 ug/ml (B) for WB. 53BP1 was immunoprecipitated using affinity purified rabbit anti-53BP1 antibody Detection: Chemiluminescence with exposure times of 3 seconds (A and B).)
IHC (Immunohistochemistry) (Detection of human and mouse Phospho 53BP1 (S25) by immunohistochemistry. Sample: FFPE sections of human stomach carcinoma (left) and mouse teratoma (right). Antibody: Affinity purified rabbit anti-Phospho 53bp1 (S25) (Cat. No. AAA211074 Lot2) used at a dilution of 1:1,000 (1ug/ml). Detection: DAB)
Protein phosphorylation is a process where a phosphate group is added to certain amino acid residues of a protein – usually serine (S), threonine (T), or tyrosine (Y) - by enzymes called kinases. This process is integral in controlling cellular signaling, cellular growth, and other biological functions.
Our catalog includes a wide range of phospho-specific antibodies that can accurately detect this important marker. They perform strongly in widely-used laboratory applications such as Western blot, flow cytometry, immunohistochemistry, and immunofluorescence microscopy. We value your trust in us and are committed to providing top-quality products and services. All of our antibodies are guaranteed to work for the applications and species indicated on our website & associated product pages.
What Are The Key Applications of Phospho Antibodies?
1. Western Blotting
One of the first steps a researcher can take in utilizing these phospho-specific antibodies, is to check if the antibody works using a technique referred to as “Western blot”. For those unfamiliar, Western Blot aids in showing whether the protein that the antibody recognizes is appearing at the correct/expected size. These phospho-specific antibodies should also be able to detect changes in the target protein’s phosphorylation (on/off state) when cells are stimulated in certain ways.
2. Staining of Fixed Cells (Immunocytochemistry)
Another routine use of these phospho-specific antibodies, is to test if the antibody is able to demonstrate similar performance when used on fixed cells (intact cells that have been preserved) as it did in the Western blot tests. It is an important aspect in many cases to confirm that the antibody works in actual intact cell samples. Ideally, the method used for cellular fixation should be the same as what is used in pathology labs (like using 10% formalin). To check if the antibody works well in tissue sections (FFPE), researchers will often test it on fixed cells that are processed similar to tissue samples.
3. Specificity Tests Using Peptides
In order to make sure that the antibody is only binding to the right target:
Laboratory technicians will mix the antibody with phospho-peptides (short segments of the protein containing the phosphate group modification).
If the antibody signal disappears, it is confirmation that it is binding to the correct phosphorylated location.
A more robust test is to use both the phosphorylated and non-phosphorylated (dephosphorylated) versions of the protein. The antibody should react only with the phosphorylated one.
Another method sometimes utilized is to treat the sample with an enzyme, such as alkaline phosphatase, that specifically removes phosphate groups. If the antibody signal disappears after this, it also confirms specificity.
4. Genetic Confirmation
As a final step, scientists can genetically manipulate the nucleotide sequence and alter the target protein by removing the exact site where phosphorylation happens. If the antibody no longer appears to detect the modified protein, it is strong evidence supporting the antibody being specific for that phosphorylated site.
Why Buy Phospho Antibodies Through Us?
The production laboratory adheres to strict and consistent protocols prior to releasing any of these phospho-specific antibodies:
Standard methods and proper controls in all tests to ensure high quality.
These antibodies are tested and validated in different cell types and species.
High quality control criterion to ensure each batch is consistent, so you will obtain reliable results every time.
FAQ
1. What Are Phospho-Specific Antibodies?
Phospho-specific antibodies are made to detect proteins only when they have a phosphate group linked to a specific amino acid residue. This empowers scientists understand if a protein is "turned on" or active, based on its phosphorylation state.
2. How to Detect Phosphorylated Proteins in a Western Blot?
To find out if a protein is phosphorylated using Western blot:
Use a phospho-specific antibody that binds only to the phosphorylated form of the protein.
You can also use a “regular” antibody for the same amino acid sequence of the protein that the phospho-specific antibody is binding to (but in this case, this antibody will not bind if there is a phosphate group present) in order to compare how much of it is phosphorylated versus how much is non-phosphorylated (or “total” protein, if the “normal” antibody’s epitopes are non-phospho-site-specific).
3. How to Choose the Best Antibody?
Here are some simple tips to help you pick the right antibody:
Know your target
Match your sample characteristics
Confirm the intended use is appropriate
Check “host” and “type”
Check the “quality” of the presented data/images
Appraise whether the available validation meets your needs
Submit a Question
Please complete the form below and a representative will contact you as soon as possible.
Request more Information
Please complete the form below and a representative will contact you as soon as possible.
Request a Manual
Please complete the form below and a representative will contact you as soon as possible.
Request a Quote
Please complete the form below and a representative will contact you as soon as possible.